Opus Bio to License CD22 CAR T Cell Technology to Juno

By | 05/12/2014

Opus Bio, Inc., today announced that Juno Therapeutics, Inc. has entered into an agreement to obtain a license for the company’s CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio. The NCI [PR.com]

Link to article: www.pr.com/press-release/595811

Category: Business Tags: ,

About PentaBytes

PentaBytes is a Blog or Digital Magazine with direct link for the best selected news in real time. The last news about Technology, Economy, Business, Startups, Society, Travel, etc. Interviews and interesting articles. You can contact with us in the contact page. Thanks.

Leave a Reply

Your email address will not be published. Required fields are marked *